Our COST Action CA-17112- ProEuroDILINet, selected as a highly innovative COST Action according to the final report «Impact Assessment Study on Innovation in COST Actions».
Three of these case studies are highlight cases: CA17112 PRO-EURO-DILI-NET; CA18114 ENTAN; CA17113 TIPICQA
The highlight cases provide particularly good examples of the different types of innovation in different contexts and stand out visually. They are followed by the other nine case studies.
Highlight Case PRO-EURO-DILI-NET: Involving relevant stakeholders from industry and regulatory agencies for groundbreaking impacts in clinical practice.
EASL Congress 2024 has now ended!
EASL Congress 2024 – OFFICIAL WEBSITE
Scientific highlights of Day 2
The Future of Hepatology session, organised in collaboration with DHILI, explored the challenges and future prospects in managing drug-induced liver injury (DILI).
Despite its rarity, DILI is a major cause of acute liver failure worldwide. The session discussed the interplay of host and drug factors that contribute to DILI, and highlighted common drug causes ranging from older medications to new biologics.
Ongoing international studies aimed at identifying predictive and diagnostic biomarkers were a key focus, emphasising the importance of understanding 4 individual risk factors for rapid and specific DILI diagnosis. The symposium underscored the need for continued research and collaboration to improve DILI management and patient outcomes.
Do we care enough about the importance of DILI/DHILI? Come to find out at the next #EASLStudio, with our faculty Guruprasad Padur Aithal, Paul Hayashi, Maribel Lucena, and Paul Watkins!
Tune in on: Wednesday, 8 May, CET
Explore the complexities, assess advancements, and discuss the obstacles hindering further progress in tackling DHILI with us. This episode is organised in collaboration with the EASL.